PRTK - パラテック・ファ―マシュ―ティカルズ (Paratek Pharmaceuticals Inc. )

PRTKのニュース

   Paratek Pharmaceuticals: Undervalued Antibiotics Play With A Fighting Chance (NASDAQ:PRTK)  2020/09/18 02:39:39 Seeking Alpha
Paratek has developed 2 antibiotics treatments - Nuzyra and Seysara - to treat different types of skin conditions.
   Paratek Pharmaceuticals : Wedbush Conference August 2020 | MarketScreener  2020/08/12 21:43:05 MarketScreener
QIDP … | August 12, 2020
   Earnings Scheduled For August 10, 2020  2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
   The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings  2020/08/09 13:05:25 Benzinga
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus treatment/vaccine news flow supported the move to the upside. Novavax, Inc.'s (NASDAQ: NVAX ) stretched valuation got further stretched as the shares added about 20% for the week in the wake of its interim Phase 1 readout for its coronavirus vaccine candidate . Bristol-Myers Squibb Co (NYSE: BMY ) reported a beat-and-raise quarter, with the shares receiving further support from a win in the patent lawsuit over its blood thinner Eliquis. The week also saw a medical technology and two biotechs debuting on the Wall Street. Here are the key catalysts for the unfolding week. Conferences BTIG Virtual Biotechnology Conference: Aug. 10-11 Wedbush PacGrow Healthcare Virtual Conference: Aug. 11-12 PDUFA Dates The FDA is said to rule on the NDA filed by Bausch Health Companies Inc (NYSE: BHC ) for EM-100, an investigational therapy for allergic conjunctivitis.
   Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences  2020/08/05 20:01:00 GlobeNewswire
BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the…
   Paratek Pharmaceuticals to Present at Two August 2020 Healthcare Conferences  2020/08/05 20:01:00 GlobeNewswire
BOSTON, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the…
   Paratek Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10, 2020  2020/07/28 20:01:00 GlobeNewswire
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the…
   Will Paratek Pharmaceuticals Continue to Surge Higher?  2020/04/28 16:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals
   Paratek Pharmaceuticals : Q4 and Full Year 2019 Financial Results & Corporate Update | MarketScreener  2020/02/25 21:37:46 MarketScreener
QIDP … | February 25, 2020
   Paratek Pharmaceuticals EPS beats by $0.16, misses on revenue  2020/02/25 21:23:17 Seeking Alpha
Paratek Pharmaceuticals (NASDAQ:PRTK): Q4 GAAP EPS of -$0.81 beats by $0.16. Revenue of $8.97M (-47.2% Y/Y) misses by $5.86M. Shares +5%. Press Release
   Will Paratek Pharmaceuticals Continue to Surge Higher?  2020/04/28 16:14:00 Zacks Investment Research
As of late, it has definitely been a great time to be an investor Paratek Pharmaceuticals
   Paratek Pharmaceuticals : Q4 and Full Year 2019 Financial Results & Corporate Update | MarketScreener  2020/02/25 21:37:46 MarketScreener
QIDP … | February 25, 2020
   Paratek Pharmaceuticals EPS beats by $0.16, misses on revenue  2020/02/25 21:23:17 Seeking Alpha
Paratek Pharmaceuticals (NASDAQ:PRTK): Q4 GAAP EPS of -$0.81 beats by $0.16. Revenue of $8.97M (-47.2% Y/Y) misses by $5.86M. Shares +5%. Press Release
   This Contrarian Play Is My Pick of the Year for 2020  2020/01/03 13:30:00 TheStreet
Paratek Pharmaceuticals (PRTK) is Bret Jensen's stock price of the year for 2020, as the antibiotics maker recently received a significant federal contract that could help give its shares the juice they need to climb next year….AXSM
   BioShield/Anthrax Contract Sets Solid Stage for Paratek Pharmaceuticals in 2020  2019/12/19 15:25:30 24/7 Wall street

calendar